Connor, Clark & Lunn Investment Management (CC&L)
MRTX

Connor, Clark & Lunn Investment Management (CC&L)’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-42,649
Closed -$1.86M – 1610
2023
Q3 		$1.86M Sell
42,649
-74,502
-64% -$2.66M 0.01% 640
2023
Q2 		$4.23M Sell
117,151
-19,335
-14% -$797K 0.02% 433
2023
Q1 		$5.07M Buy
+136,486
New +$6.14M 0.03% 367
2022
Q1 		– Sell
-20,751
Closed -$3.04M – 1262
2021
Q4 		$3.04M Buy
+20,751
New +$3.22M 0.01% 438
2021
Q2 		– Sell
-4,448
Closed -$762K – 1138
2021
Q1 		$762K Buy
4,448
+1,435
+48% +$284K ﹤0.01% 733
2020
Q4 		$662K Buy
+3,013
New +$651K ﹤0.01% 689
2017
Q3 		– Sell
-15,900
Closed -$58K – 939
2017
Q2 		$58K Buy
15,900
+100
+0.6% +$383 ﹤0.01% 798
2017
Q1 		$82K Buy
+15,800
New +$86.6K ﹤0.01% 863

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s MRTX Position: Q4 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 42,649 shares — an estimated $1.86M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in MRTX in Q1 2017 and held it in 8 quarters. The position peaked at $5.07M in Q1 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 42,649 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $1.86M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2017 and held it in 8 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Mirati Therapeutics, Inc. Common Stock position peaked at $5.07M in Q1 2023.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2023, filed 9 Feb 2024.